Keywords: ucb, absorbs, zyrtec, patent, expiry, profit, still
UCB absorbs Zyrtec patent expiry, but 2008 profit still down 74% on restructuring charges
Article | 09 March 2009
Belgian drugmaker UCB's 2008 profit fell 74% year-on-year as the company's lead product, Zyrtec (cetirizine HCl), faced generic competition in the USA. ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
